This issue of the Singapore Medical Journal focuses on Cardiology and the papers are curated to highlight the ongoing research and hot topics in this field.
The review article on pulmonary hypertension (PH) in pregnancy is a collaborative effort between the Department of Obstetrics and Gynaecology and Department of Cardiology of National University Hospital, Singapore.[1] Ong et al. explored the associations between PH and pregnancy, which sometimes are encountered concomitantly and often result in negative maternal and fetal outcomes. However, with the emergence of recent new treatment options, both morbidity and mortality associated with PH in pregnancy have improved. The review provides contemporary updates in the management of pre-capillary and post-capillary PH. Accompanying the review is an article in the electrocardiography series that includes two cases to illustrate several aspects of managing PH in pregnancy.[2]
Next, Dalakoti et al. discuss preventive cardiology, an area that Singapore has focused on through Healthier SG, a national initiative by the Ministry of Health, Singapore.[3] The authors emphasise that subclinical atherosclerosis represents a key prevention strategy for early intervention. The importance of early detection and management of conventional as well as newer risk factors are reinforced. The lifetime goal of targeting lower levels of low-density lipoprotein cholesterol (LDL-C) and glycated haemoglobin, along with education may indeed shift the trajectory of cardiovascular disease and reduce major adverse events, resulting in improved population health.
Mak et al. conducted a prospective observational cohort study of patients with ischaemic heart disease admitted to the hospital.[4] They found treatment gaps in lipid management in a large proportion of the local population, with the use of statin monotherapy in the majority resulting in insufficient efficacy to achieve LDL-C goals. This is consistent with previous studies published locally[5] and in the region.[6] Furthermore, like many landmark studies, Mak et al. demonstrated that lower LDL-C levels were associated with reduction of all-cause mortality within as little as 24 months. Not every patient believes in the LDL-C hypothesis (now an established principle) due to the myths from the Internet and false social media influences. Public education will be key to drive home important messages. Community cardiology can help augment this push.[7] Furthermore, with the recent approvals of anti-proprotein convertase subtilisin/kexin type 9 monoclonal antibody and inclisiran injectables,[8] we hope for wider adoption of these efficacious therapy. Together with oral ezetimide use,[9] we aim to increase our armamentarium to reduce adverse event rates. The recent cost-effectiveness analyses should also reassure funders and policy makers.[10]
In addition, this issue includes an article focusing on use of computed tomography (CT) to quantify coronary calcification in primary care.[11] Coronary artery calcium scores can predict future cardiac events and correlates with the extent of coronary artery disease. However, it is not uncommon to see non-calcified plaques in CT coronary angiogram, and more research and insights using this modality is underway.
Finally, Xu et al. conducted a cross-sectional study investigating the association between vascular function and bone mineral density (BMD) in patients with rheumatoid arthritis.[12] They found that lower BMD at the lumbar spine, femoral neck and total hip was associated with worse natural logarithm reactive hyperaemia index, a parameter of endothelial dysfunction. Further studies to determine the underlying mechanisms will be valuable and insightful.
We hope you will enjoy this issue, which not only highlights preventive cardiology and community care , but also includes articles on ‘cardiology plus’ (cardiology and other specialties). Moving forward, we expect increased collaborations between cardiology and various subspecialties, as well as multidisciplinary approaches aimed at achieving better outcomes for patients.
REFERENCES
- 1.Ong JYS, Yap JJY, Choolani M, Poh KK, Dashraath P, Low TT. Cardiovascular–obstetric state-of-the-art review:pulmonary hypertension in pregnancy. Singapore Med J. 2025;66:130–40. doi: 10.4103/singaporemedj.SMJ-2024-198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Ong JYS, Yap JJY, Dashraath P, Low TT, Choolani M, Poh KK. Pulmonary hypertension in pregnancy:two sides to a coin. Singapore Med J. 2025;66:167–71. doi: 10.4103/singaporemedj.SMJ-2024-205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Dalakoti M, Chen CK, Sia CH, Poh KK. Frontiers in subclinical atherosclerosis and the latest in early life preventive cardiology. Singapore Med J. 2025;66:141–6. doi: 10.4103/singaporemedj.SMJ-2024-169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Mak YH, Chua F, Koh XH, Tan VH, Lee ZH, Lam A, Tong KL, et al. Low-density lipoprotein cholesterol goal attainment and mortality in ischaemic heart disease:a two-year observational study. Singapore Med J. 2025;66:154–62. doi: 10.4103/singaporemedj.SMJ-2024-172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Poh KK, Chin CT, Tong KL, Tan JKB, Lim JS, Yu W, et al. Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore:results from the Dyslipidemia International Study II. Singapore Med J. 2019;60:454–62. doi: 10.11622/smedj.2019021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Poh KK, Ambegaonkar B, Baxter CA, Brudi P, Buddhari W, Chiang FT, et al. Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region:results from the Dyslipidemia International Study II. Eur J Prev Cardiol. 2018;25:1950–63. doi: 10.1177/2047487318798927. [DOI] [PubMed] [Google Scholar]
- 7.Lim TW, Lim YW. Cardiology in the community:integrating care through professional communication in Singapore. Singapore Med J. 2025;66:127–9. doi: 10.4103/singaporemedj.SMJ-2024-164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Huo Y, Lesogor A, Lee CW, Chiang CE, Mena-Madrazo J, Poh KK, et al. Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18. JACC Asia. 2023;4:123–34. doi: 10.1016/j.jacasi.2023.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Chong E, Shen L, Poh KK. Half-dose ezetimibe add-on to statin therapy is effective in improving resistant hyperlipidaemia in Asian patients with ischaemic heart disease. Singapore Med J. 2011;52:400–4. [PubMed] [Google Scholar]
- 10.Lim YL, Tan RS, Poh KK, Wang XJ. Cost-Effectiveness Analysis of Inclisiran for the Treatment of Primary Hypercholesterolemia or Mixed Dyslipidemia in Singapore. Value Health Reg Issues. 2025 doi: 10.1016/j.vhri.2024.101067. Jan 15:101067. doi:10.1016/j.vhri.2024.101067. Epub ahead of print. [DOI] [PubMed] [Google Scholar]
- 11.Lee E, Koh S, Sia CH. Coronary artery calcium scoring in primary care. Singapore Med J. 2025;66:163–6. doi: 10.4103/singaporemedj.SMJ-2024-211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Xu C, Lai YW, Chou SH, Zhang X, Koh ET, Dalan R, et al. Association between bone mineral density and vascular health in rheumatoid arthritis. Singapore Med J. 2025;66:147–53. doi: 10.4103/singaporemedj.SMJ-2024-183. [DOI] [PMC free article] [PubMed] [Google Scholar]
